Some studies showed that MM cells with an IL-6-activated JAK/STAT3 pathway are particularly sensitive to heat shock protein 90 (Hsp90) inibitors [43], making this a potential therapeutic target for the FHR MM patients. Here, IL6 is linked to Miyoshi myopathy.